Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Chuan ^a   Chen, Minyan ^a   Fu, Fangmeng ^a   Huang, Meng ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; GONADORELIN;

ADD ON THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; HUMAN; MENSTRUATION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OVARY FUNCTION; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METABOLISM; OVARY; PATHOPHYSIOLOGY; PROCEDURES;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MENSTRUATION; OVARY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879275552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066360     Document Type: Article

References (28)

1. Surveillance, Epidemiology and End Results (SEER) (2010) Available: http://www.seer.cancer.gov.Based on the November 2009 submission. Accessed June 20, 2011.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics 2010. CA Cancer J Clin 60: 277-300.
3. Klimm B, Schnell R, Diehl V, Engert A, (2005) Current treatment and imm unotherapy of Hodgkin's lymphoma. Haematologica 90: 1680-1692.
4. Olopade OI, Grushko TA, Nanda R, Huo D, (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14: 7988-7999.
5. Blumenfeld Z, (2003) Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 15: 359-370.
6. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM, (2002) Fertility after treatment for Hodgkin's disease. Ann Oncol 13 (Suppl1): 138-147.
7. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, et al. (2007) Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 43: 1646-1653.
8. Shenns RJ (1993) Gonadal dysfunction. In: DeVita VTJ, Hellma NS, Rosenberg SA, editors. Cancer-principles and practice of oncology. Philadelphia: J.B. Lippincott.
9. Suzuki N, Yoshioka N, Sugishita Y, Takae S, Horage Y, et al. (2012) The possibility of the fertility preservation in young cancer patients based on practice of oncofertility treatment. Gan Uo Kagaku Ryoho 39(2): 151-157.
10. Decanter C, Gligorov J, (2011) Oocyte/embryo cryopreservation before chemotherapy for breast cancer. Gynecol Obstet Fertil 39(9): 501-503.
11. Sutcliffe SB, (1979) Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease: facts and thoughts. JAMA 242: 1898-1899.
12. Ataya K, Rao LV, Lawrence E, Kimmel R, (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophospha-mide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52: 365-372.
13. Ataya K, Ramahi-Ataya A, (1993) Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 7: 229-235.
14. Bokser L, Szende B, Schally AV, (1990) Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 61: 861-865.
15. Badawy A, Elnashar A, El-Ashry M, Shahat M, (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91: 694-697.
16. Munster PN, Moore AP, Ismail-Khan R, E Cox, Lacevic M, et al. (2012) Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer. J Clin Oncol 30: 533-538.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
18. Jianling B, Wenzhao Z, Minghua Z, Feng C, (2007) Meta- Analysis in Stata. The Journal of Evidence-Based Medicine 6: 363-368.
19. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
20. Der Simonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
21. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple graphical test. BMJ 315: 629-634.
22. Gerber B, Stehle H, Ricardo F, Minckwitz G, Reimer T, et al. (2011) Effect of Luteinizing Hormone-Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study. J Clin Oncol 29: 2334-2341.
23. Sverrisdottir A, Nystedt M, Johansson H, Fornander T, (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117: 561-567.
24. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, et al. (2011) Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer: A Randomized Trial. JAMA 306: 269-276.
25. Li M, Huang H, Liang Y, Tan J, Lin D, (2008) Effect of Zoladex Administered before Chemotherapy on Menstruation of Patients with Breast Cancer. Chinese Journal of Clinical Oncology 35: 905-907.
26. Sun J, Ren Y, Li W, (2011) Effect of Zoladex Administered before Chemotherapy on Menstruation of Patients with Breast Cancer. China Disability Medicine 19: 15-16.
27. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, et al. (2009) Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 18: 311-319.
28. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, et al. (2011) Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 95: 906-914.